Get the Stockscreener App
73.37
2.56%
1.83
After Hours:
73.37
Dexcom Inc stock is traded at $73.37, with a volume of 5.00M.
It is up +2.56% in the last 24 hours and up +4.61% over the past month.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
See More
Previous Close:
$71.54
Open:
$72
24h Volume:
5.00M
Relative Volume:
0.90
Market Cap:
$28.31B
Revenue:
$4.82B
Net Income/Loss:
$930.40M
P/E Ratio:
31.38
EPS:
2.3381
Net Cash Flow:
$1.43B
1W Performance:
-3.07%
1M Performance:
+4.61%
6M Performance:
-0.41%
1Y Performance:
-17.55%
1-Day Range:
$72.00
$74.59
1-Week Range:
$69.79
$76.95
52-Week Range:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
73.37 | 27.61B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
104.49 | 179.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
336.74 | 126.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
84.22 | 106.51B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
45.51 | 65.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
83.04 | 47.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-12-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-25-25 | Initiated | Evercore ISI | In-line |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-21-25 | Initiated | Argus | Buy |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-03-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-24 | Initiated | Redburn Atlantic | Neutral |
| Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
Stryker's Q2 Results Likely to Reflect Recovery of Q1 Deferred Orders - TradingView
DXCM Q2 Results Likely to Reflect Strong G7 & Reimbursement Expansion - TradingView
Dexcom stock trades near 52-week high as continuous glucose monitoring growth supports valuation - Ad-hoc-news.de
Dexcom Inc (DXCM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Dexcom Inc (DXCM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dexcom Inc (DXCM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Dexcom Selected as First Manufacturer in FDA's Innovative Digital Health Outcomes Program - HCI Innovation Group
Dexcom Inc (DXCM) Balance Sheet - TradingKey
Dexcom stock trades steady as glucose-monitoring growth supports valuation - Ad-hoc-news.de
Dexcom Inc|Price:71.540|Chg%:+1.060 - TradingKey
Does DexCom’s (DXCM) Longer-Wear G7 Approval Hint At A Durable Edge In Connected Diabetes Care? - simplywall.st
Dexcom stock trades near recent highs as diabetes tech growth supports valuation - AD HOC NEWS
FDA selects Dexcom as first participant in TEMPO pilot for digital health devices - MedTech World
DexCom Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
DXCM|Dexcom Inc|Price:73.585|Chg%:+2.045 - TradingKey
Dexcom Gets First Slot In FDA-CMS Pilot That Rewards Real-World Data At Scale - insights.citeline.com
Dexcom Inc (DXCM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
FDA names Dexcom as first participant in digital health pilot - MedTech Dive
DexCom (DXCM) Earnings Expected to Grow: Should You Buy? - Yahoo Finance Singapore
Dexcom Kicks Off FDA’s TEMPO Digital Health Device Pilot - Medical Product Outsourcing
Dexcom (DXCM) Chosen as First Participant in FDA's TEMPO Pilot - GuruFocus
Dexcom stock trades near record levels as glucose monitoring demand supports growth - Ad-hoc-news.de
Dexcom (DXCM) Selected for FDA's TEMPO Pilot Program to Enhance Glucose Monitoring - GuruFocus
DexCom, Inc.'s Stock Price Drops to $71.43, Marking a 4.44% Decrease: Uncovering the Reasons Behind the Downfall - Smartkarma
A Look at DexCom Inc (DXCM) After 4.4% Decline -- GF Value $104.58 vs Price $71.43 - GuruFocus
A Look at DexCom Inc (DXCM) After 4.4% Decline -- GF Value $104. - GuruFocus
Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program - Dexcom Investor Relations
DexCom Inc. stock underperforms Wednesday when compared to competitors - MSN
At US$74.75, Is It Time To Put DexCom, Inc. (NASDAQ:DXCM) On Your Watch List? - Moomoo
Dexcom Selected as First Participant in FDA's TEMPO Pilot Program - Intellectia AI
Dexcom Executive Chair Kevin R. Sayer Disposes of 26,756 Shares via Prearranged Rule 10b5-1 Plan - Kalkine Media
Dexcom Inc (DXCM) chair Kevin Sayer sells 26,756 shares under 10b5-1 plan - Stock Titan
DexCom Inc. stock outperforms competitors despite losses on the day - MarketWatch
Dexcom stock trades near 52-week high as G7 CGM growth supports earnings momentum - AD HOC NEWS
Are Medical Stocks Lagging DexCom (DXCM) This Year? - Yahoo Finance
DexCom Inc. stock underperforms Monday when compared to competitors - MarketWatch
Dexcom (NASDAQ: DXCM) executive plans 26,756-share stock sale - Stock Titan
Dexcom stock trades steady as diabetes CGM growth supports earnings outlook - Ad-hoc-news.de
Dexcom Inc. stock underperforms Thursday when compared to competitors despite daily gains - MSN
Dexcom stock holds steady as investors weigh Q1 2026 growth - ad-hoc-news.de
Enterprise value to EBIT forward of DexCom, Inc. – FWB:DC4 - TradingView
DexCom (DXCM) Back In Focus As Canada Approval Tests Its Valuation - Sahm
Dexcom stock trades steady as diabetes technology growth supports valuation - ad-hoc-news.de
DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch
DexCom Inc. Stock Climbs 7.2%, Outperforms Market - webull.com
DXCM5813816 Bond Profile — Key Metrics - TradingView
Form 4 DexCom Inc For: 16 July By Investing.com - Investing.com Nigeria
Dexcom stock trades steady as CGM demand supports revenue growth - ad-hoc-news.de
Truist raises DexCom stock price target to $87 on growth outlook By Investing.com - Investing.com South Africa
Dexcom EVP chief legal compliance off sells $126,514 in stock By Investing.com - Investing.com Nigeria
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.89%
4.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):